<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03269084</url>
  </required_header>
  <id_info>
    <org_study_id>1-SRA-2016-342-M-R</org_study_id>
    <nct_id>NCT03269084</nct_id>
  </id_info>
  <brief_title>Type 1 Diabetes Prediction and Prevention (DIPP) Study</brief_title>
  <acronym>DIPP</acronym>
  <official_title>Type 1 Diabetes Prediction and Prevention (DIPP) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Riitta Veijola</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Oulu University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Turku</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Turku University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Tampere</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tampere University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Juvenile Diabetes Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Leona M. and Harry B. Helmsley Charitable Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Oulu</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Type 1 Diabetes Prediction and Prevention (DIPP) Study in Finland is a population-based
      long-term clinical follow-up study established since 1994 in three university hospitals in
      Finland to understand the pathogenesis of type 1 diabetes (T1D), predict the disease, and
      find preventive treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Briefly, cord blood samples are collected and HLA-DR-DQ genotypes are determined from newborn
      babies. Families with a newborn baby carrying a DR-DQ genotype associated with increased risk
      for T1D are invited to participate in regular follow-up at the age of 3, 6, 9, 12, 18 and 24
      months, and thereafter once a year until the age of 15 years or until T1D is diagnosed.
      Clinical details including maternal diet during pregnancy and lactation and child's diet
      starting from the age of 3 months are recorded, blood samples are collected, and serum
      autoantibodies associated with development of T1D are measured. Children who develop
      beta-cell specific autoimmunity are followed more intensively with measurements of glucose
      metabolism parameters such as glycated haemoglobin A1c (HbA1c), oral glucose tolerance tests
      (OGTT) and intravenous glucose tolerance tests (IVGTT). In the DIPP Study more than 1000
      children have developed multiple islet autoantibodies and more than 450 of these have
      progressed to clinical T1D. It has been estimated that 5% of children in the follow-up will
      develop T1D and 60% of future T1D cases will be reached by the current screening and
      follow-up strategy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 7, 1994</start_date>
  <completion_date type="Anticipated">December 31, 2017</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Positivity for at least one islet autoantibody</measure>
    <time_frame>December 31, 2017</time_frame>
    <description>ICA, IAA, GADA, IA-2A or ZnT8A</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical diagnosis of type 1 diabetes</measure>
    <time_frame>December 31, 2017</time_frame>
    <description>Hyperglycemia as defined by WHO</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">17000</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Children at HLA-conferred risk for T1D</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention. DIPP is an observational study.</intervention_name>
    <arm_group_label>Children at HLA-conferred risk for T1D</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Since November 1994 the Finnish Type 1 Diabetes Prediction and Prevention (DIPP) Study has
        screened 206,707 newborns for HLA-conferred genetic susceptibility for T1D (Figure 1., data
        as of March 2015). A total of 16,193 children have started clinical follow-up with regular
        study visits and systematic collection of longitudinal blood and stool samples. Altogether
        more than 1000 children have seroconverted to positivity for multiple islet autoantibodies
        (ICA included). A total of 461 children and adolescents have progressed to clinical T1D
        with DIPP follow-up from birth until diagnosis. Currently there are 7158 children between 3
        months and 15 years of age taking part in the DIPP Study follow-up.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newborn babies with HLA-conferred genetic susceptibility to type 1 diabetes born in
             three University Hospitals in Finland

        Exclusion Criteria:

          -  Newborn babies without HLA-conferred genetic susceptibility to type 1 diabetes
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Riitta Veijola, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oulu, Oulu University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mikael Knip, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Helsinki, Tampere University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jorma Toppari, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Turku, Turku University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jorma Ilonen, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Turku</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Heikki Hy√∂ty, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Tampere</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Riitta Veijola, MD PhD</last_name>
    <phone>+358407422328</phone>
    <email>riitta.veijola@oulu.fi</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Oulu and Oulu University Hospital</name>
      <address>
        <city>Oulu</city>
        <zip>90029</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Riitta Veijola, MD</last_name>
      <phone>+358 8 3155129</phone>
      <email>riitta.veijola@oulu.fi</email>
    </contact>
    <investigator>
      <last_name>Riitta Veijola, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Tampere and Tampere University Hospital</name>
      <address>
        <city>Tampere</city>
        <zip>33520</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mikael Knip, MD</last_name>
      <email>mikael.knip@helsinki.fi</email>
    </contact>
    <investigator>
      <last_name>Mikael Knip, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Turku and Turku University Hospital</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jorma Toppari, MD</last_name>
      <email>jorma.toppari@utu.fi</email>
    </contact>
    <investigator>
      <last_name>Jorma Toppari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 30, 2017</study_first_submitted>
  <study_first_submitted_qc>August 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2017</study_first_posted>
  <last_update_submitted>August 30, 2017</last_update_submitted>
  <last_update_submitted_qc>August 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Oulu</investigator_affiliation>
    <investigator_full_name>Riitta Veijola</investigator_full_name>
    <investigator_title>Professor of Pediatrics</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

